Healthcare provider profile · identity verified

Carl A Meyer, MD

Hospitalist · MEDIA, PA · NPI 1215945985

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	648	193
Amlodipine Besylate	Amlodipine Besylate	418	117
Levothyroxine Sodium	Levothyroxine Sodium	304	86
Lisinopril	Lisinopril	284	85
Rosuvastatin Calcium	Rosuvastatin Calcium	256	79
Losartan Potassium	Losartan Potassium	230	67
Simvastatin	Simvastatin	224	64
Hydrochlorothiazide	Hydrochlorothiazide	190	55
Lorazepam	Lorazepam	172	31
Metoprolol Succinate	Metoprolol Succinate	169	50
Omeprazole	Omeprazole	162	50
Metformin Hcl Er	Metformin Hcl	158	45
Metformin Hcl	Metformin Hcl	137	42
Pantoprazole Sodium	Pantoprazole Sodium	124	34
Sertraline Hcl	Sertraline Hcl	123	32
Tamsulosin Hcl	Tamsulosin Hcl	121	42
Escitalopram Oxalate	Escitalopram Oxalate	114	31
Alprazolam	Alprazolam	109	22
Furosemide	Furosemide	109	29
Gabapentin	Gabapentin	99	33
Fluticasone Propionate	Fluticasone Propionate	98	33
Allopurinol	Allopurinol	96	28
Pravastatin Sodium	Pravastatin Sodium	85	24
Eliquis	Apixaban	75	19
Potassium Chloride	Potassium Chloride	75	18
Synthroid	Levothyroxine Sodium	75	23
Zolpidem Tartrate	Zolpidem Tartrate	67	18
Montelukast Sodium	Montelukast Sodium	64	19
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	63	16
Albuterol Sulfate Hfa	Albuterol Sulfate	62	21
Ozempic	Semaglutide	60	suppressed
Tramadol Hcl	Tramadol Hcl	60	16
Irbesartan	Irbesartan	57	20
Oxycodone Hcl	Oxycodone Hcl	57	suppressed
Trulicity	Dulaglutide	55	12
Ezetimibe	Ezetimibe	52	16
Prednisone	Prednisone	52	44
Metoprolol Tartrate	Metoprolol Tartrate	51	17
Clopidogrel	Clopidogrel Bisulfate	46	14
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	46	13
Fluoxetine Hcl	Fluoxetine Hcl	44	14
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	44	13
Finasteride	Finasteride	42	13
Januvia	Sitagliptin Phosphate	41	11
Valsartan	Valsartan	41	11
Carvedilol	Carvedilol	40	17
Cyclobenzaprine Hcl	Cyclobenzaprine Hcl	40	12
Mounjaro	Tirzepatide	39	suppressed
Atenolol	Atenolol	38	11
Warfarin Sodium	Warfarin Sodium	38	suppressed
Famotidine	Famotidine	37	18
Jardiance	Empagliflozin	36	12
Nitrofurantoin	Nitrofurantoin Macrocrystal	36	26
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	35	suppressed
Ramipril	Ramipril	35	suppressed
Trazodone Hcl	Trazodone Hcl	35	12
Enalapril Maleate	Enalapril Maleate	34	suppressed
Valacyclovir	Valacyclovir Hcl	33	11
Azithromycin	Azithromycin	32	29
Glipizide Er	Glipizide	31	suppressed
Pregabalin	Pregabalin	30	suppressed
Donepezil Hcl	Donepezil Hcl	28	suppressed
Ibuprofen	Ibuprofen	28	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	27	suppressed
Ondansetron Odt	Ondansetron	27	suppressed
Tizanidine Hcl	Tizanidine Hcl	27	suppressed
Acetaminophen-Codeine	Acetaminophen With Codeine	25	suppressed
Chlorthalidone	Chlorthalidone	25	suppressed
Citalopram Hbr	Citalopram Hydrobromide	25	suppressed
Mirtazapine	Mirtazapine	25	suppressed
Triamterene-Hydrochlorothiazid	Triamterene/Hydrochlorothiazid	24	suppressed
Dextroamphetamine-Amphetamine	Dextroamphetamine/Amphetamine	23	suppressed
Spironolactone	Spironolactone	23	suppressed
Sumatriptan Succinate	Sumatriptan Succinate	23	suppressed
Latanoprost	Latanoprost	22	suppressed
Xarelto	Rivaroxaban	22	suppressed
Doxazosin Mesylate	Doxazosin Mesylate	20	suppressed
Lansoprazole	Lansoprazole	20	suppressed
Bupropion Xl	Bupropion Hcl	19	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	19	suppressed
Meloxicam	Meloxicam	18	suppressed
Zolpidem Tartrate Er	Zolpidem Tartrate	18	suppressed
Glipizide	Glipizide	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	17
Sulfamethoxazole-Trimethoprim	Sulfamethoxazole/Trimethoprim	17	15
Diazepam	Diazepam	16	suppressed
Duloxetine Hcl	Duloxetine Hcl	16	suppressed
Myrbetriq	Mirabegron	16	suppressed
Terazosin Hcl	Terazosin Hcl	16	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Candesartan Cilexetil	Candesartan Cilexetil	14	suppressed
Clonazepam	Clonazepam	14	suppressed
Doxycycline Hyclate	Doxycycline Hyclate	14	13
Ketoconazole	Ketoconazole	14	suppressed
Olmesartan Medoxomil	Olmesartan Medoxomil	14	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	14	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	14	suppressed
Amoxicillin	Amoxicillin	13	suppressed
Irbesartan-Hydrochlorothiazide	Irbesartan/Hydrochlorothiazide	13	suppressed
Isosorbide Mononitrate Er	Isosorbide Mononitrate	13	suppressed
Lovastatin	Lovastatin	13	suppressed
Paroxetine Hcl	Paroxetine Hcl	13	suppressed
Tramadol Hcl Er	Tramadol Hcl	13	suppressed
Acetazolamide	Acetazolamide	12	suppressed
Celebrex	Celecoxib	12	suppressed
Dicyclomine Hcl	Dicyclomine Hcl	12	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	12	suppressed
Meclizine Hcl	Meclizine Hcl	12	suppressed
Methylphenidate Er	Methylphenidate Hcl	12	suppressed
Naproxen	Naproxen	12	suppressed
Triamcinolone Acetonide	Triamcinolone Acetonide	12	suppressed
Alendronate Sodium	Alendronate Sodium	11	suppressed
Buspirone Hcl	Buspirone Hcl	11	suppressed
Celecoxib	Celecoxib	11	suppressed
Diltiazem 24hr Er	Diltiazem Hcl	11	suppressed
Ondansetron Hcl	Ondansetron Hcl	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error